AAVs are widely used as viral vectors in human gene therapy implementing recombinant DNA technology. Measurement of AAV concentration in complex biological matrices is essential for and effective manufacturing of AAV gene therapies.
Revvity has developed and manufactured a line of immunoassays that detect and quantify AAV capsid with AlphaLISA™ technology. These assays can detect AAV1, AAV2, AAV3B, AAV5, AAV6, AAV8, and AAV9 serotypes, and measure AAV particles present in cell culture media, lysis buffer, and cell lysate.
Get your application note to:
For research use only. Not for use in diagnostic procedures.
AAV capsid detection and characterization with new AlphaLISA assay kits